Laura Cuzzolin Pages 167 - 173 ( 7 )
Physiological changes occurring perinatally and in the first month of life can affect the answer to a pharmacological treatment and the individual response to a drug in terms of efficacy and toxicity is highly variable in the neonatal population. Among potential causes for such variability, differences in drug metabolism may have a great impact.
This article aims to review qualitative and quantitative differences in drug metabolizing enzymes in neonates, since both phase I and phase II metabolic pathways are immature at birth and subject to maturational changes in the first period of extrauterine life.
Moreover, clinical implications will be discussed.
Newborns, drugs, enzymes, Drug Metabolizing Enzymes, Perinatal, Neonatal Period, toxicity, phase II, CYP2C, CYP3A5, Sulfation
Department of Public Health & Community Medicine-Section of Pharmacology, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 37134 Verona, Italy.